The effectiveness of these inhibitors may be attributed to the restoration of the immune system ability to recognize and attack tumor cells by inhibiting the PD-1/PD-L1 pathway, which is often exploited by cancer cells for immune evasion. Here, PDCD1 is linked to cancer.